bioMérieux Reports Q3 2026 Revenue Exceeding Analyst Expectations

bioMérieux reported Q3 2026 revenue of €1.04 billion, up 9.9% year over year on a reported basis and 8.1% organically, exceeding analyst expectations of €1.01 billion and 5.9% organic growth. The company confirmed its 2026 objectives of 3% to 5% organic revenue growth and contributive operating income that is stable or increases by up to 10% organically.